ELEVIDYS Shows Durable Functional Benefit in Older Duchenne Patients, New Data Reveals
SRPT sits 27% above its 52-week low of $14.68.
Summary
Sarepta presented new data at WMS 2026 showing ELEVIDYS provides clinically meaningful functional benefit in older ambulatory Duchenne patients (ages 8-12), with a 3.32-point NSAA improvement vs external control (p=0.0022) sustained over two years. This expands the evidence base beyond the currently approved 4-7 age group and supports potential label expansion. Safety was manageable and consistent with prior data. The company also showed robust micro-dystrophin expression in 2-3 year-olds, suggesting earlier treatment may yield higher expression. These data strengthen the case for broader use of ELEVIDYS, though regulatory approval for older patients is not yet secured. The stock may react positively as this addresses a key commercial question about the drug's applicability to a larger patient population.
At the time of this announcement, SRPT was trading at $18.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $14.68 to $25.32. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.